Related Experiment Video
Updated: May 11, 2025
10:03
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
10.4K
α-Synuclein Pathology Spreads in a Midbrain-Hindbrain Assembloid Model.
Gemma Gomez-Giro1, Daniela Frangenberg1, Daniela Vega1
1Developmental and Cellular Biology, Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Belvaux, L-4367, Luxembourg.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|April 17, 2025
Summary
A new midbrain-hindbrain organoid model shows how alpha-synuclein pathology spreads in Parkinson's disease (PD). This model helps study disease progression and test new PD therapies.
Area of Science:
- Neuroscience
- Pathology
- Biotechnology
Background:
- Alpha-synuclein (α-synuclein) pathology is central to Parkinson's disease (PD) and related synucleinopathies.
- Understanding the mechanisms of α-synuclein spreading is crucial for developing effective treatments.
- Current models often fail to fully recapitulate the complex progression of PD pathology.
Purpose of the Study:
- To develop and validate a novel in vitro model for studying α-synuclein pathology propagation.
- To investigate the transfer of α-synuclein pathology from hindbrain to midbrain regions.
- To establish a platform for screening potential therapeutics for PD and synucleinopathies.
Main Methods:
- Development of hindbrain organoids.
- Tissue engineering to create midbrain-hindbrain assembloids.
- In vitro assessment of α-synuclein pathology spread and synaptic changes.
Main Results:
- Demonstrated α-synuclein pathology in hindbrain organoids.
- Successfully created midbrain-hindbrain assembloids that mimic PD pathology progression.
- Observed transfer of α-synuclein pathology from hindbrain to midbrain, inducing synaptic alterations.
Conclusions:
- The midbrain-hindbrain assembloid model effectively recapitulates PD-associated α-synuclein spreading.
- This model provides a robust platform for mechanistic studies of α-synuclein propagation.
- The model holds promise for therapeutic screening in Parkinson's disease and related disorders.
